Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...
One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback